SANOFI DEC8 Stock Euronext Paris
Stocks
SANZ8
FR0000884041
Pharmaceuticals
OTC Markets Traded| Market Cap | 90.48B 0 105B 85.11B 77.32B 145B 9,986B 148B 997B 390B 5,015B 393B 385B 16,669B | P/E 2026 * |
12x | P/E 2027 * | 10.5x |
|---|---|---|---|---|---|
| Enterprise Value | 102B 0 118B 95.84B 87.07B 164B 11,245B 166B 1,122B 439B 5,648B 442B 433B 18,772B | EV / Sales 2026 * |
2.14x | EV / Sales 2027 * | 1.95x |
| Free-Float |
88.34% | Yield 2026 * |
5.63% | Yield 2027 * | 5.96% |
Last Transcript: SANOFI DEC8
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 57 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 105B | |
| -2.25% | -0.47% | +68.30% | +115.90% | 1,052B | |
| -0.66% | +0.43% | +47.39% | +50.54% | 627B | |
| -0.54% | +1.39% | +20.69% | +63.99% | 441B | |
| -1.99% | -3.32% | +38.71% | +35.41% | 349B | |
| -1.05% | -2.81% | +23.07% | +35.70% | 287B | |
| -2.12% | -3.67% | -1.14% | +5.37% | 241B | |
| -0.63% | +1.04% | +40.05% | +56.09% | 224B | |
| -1.19% | -3.41% | -9.57% | -52.71% | 202B | |
| +0.16% | +3.87% | +16.89% | +73.73% | 172B | |
| Average | -1.03% | +0.43% | +27.15% | +42.67% | 399.46B | |
| Weighted average by Cap. | -1.32% | +0.32% | +39.09% | +61.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.59B 0 55.09B 44.77B 40.67B 76.39B 5,253B 77.71B 524B 205B 2,638B 207B 202B 8,768B | 50.7B 0 58.69B 47.69B 43.33B 81.38B 5,596B 82.8B 559B 218B 2,811B 220B 216B 9,341B |
| Net income | 7.94B 0 9.19B 7.47B 6.79B 12.75B 876B 12.97B 87.48B 34.19B 440B 34.47B 33.75B 1,463B | 9.27B 0 10.73B 8.72B 7.92B 14.87B 1,023B 15.13B 102B 39.9B 514B 40.23B 39.39B 1,707B |
| Net Debt | 11.42B 0 13.21B 10.74B 9.75B 18.32B 1,260B 18.64B 126B 49.15B 633B 49.55B 48.52B 2,103B | 8.23B 0 9.53B 7.74B 7.03B 13.21B 909B 13.44B 90.69B 35.44B 456B 35.74B 34.99B 1,517B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
